[Oncological treatment modalities in head and neck cancer].
Intensity-modulated radiotherapy (IMRT) can be applied to reduce the radiation dose for healthy tissues and lessen adverse effects. It can be used to increase the efficiency of treatment, for example by applying the radiotherapy in two small daily fractions instead of the usual one fraction, or by accelerated fractionation, in which the radiotherapy is also given twice a day, but with larger daily doses. With the exception of early-stage tumors, chemoradiotherapy has become an established treatment modality for tumors. The most commonly used cytotoxic agent is cisplatin, the second being cetuximab, a monoclonal antibody targeting cancer cells via the epidermal growth factor.
HYKS:n syöpätautien klinikka, sädehoito-osasto.
Kauko
K
Saarilahti
Paula
P
Lindholm
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab; D002945:Cisplatin